As the authors point out, failed psychopharmacologic randomized controlled trials are common but poorly understood. In the companion article, 2 the authors describe the analyses from computer-based assessments to examine the impact of eligibility criteria in more detail. The major finding was that, on the basis of computer assessments, nearly two-thirds of randomized subjects failed to meet at least 1 protocol-specified eligibility criterion. As the authors indicate, the enrollment of ineligible subjects may contribute to the failure of acute psychopharmacologic efficacy studies.
T
his issue of the Journal includes companion articles by Sachs and collaborators. 1, 2 The first one describes a failed/negative study of adjunctive ziprasidone combined with lithium or divalproex compared to lithium or divalproex monotherapy. The second article addresses the influence of protocol-specific eligibility criteria on signal detection.
The investigators followed a similar design of a study 3 utilizing another atypical antipsychotic agent that was published a decade ago, which was replicated with other antipsychotic agents in subsequent years. [4] [5] [6] The present study, however, also utilized computer-assisted ratings. Importantly, the present and previous studies included a population that had not responded adequately to lithium or divalproex.
The study results suggest that when patients do not adequately respond to lithium or divalproex, the addition of ziprasidone does not provide additional value. 1 Of note, previous trials with other treatments required subjects being on a therapeutic dose of a mood stabilizer for at least 2 weeks, while the current study required only 3-7 days. A separate question not answered by this study is the difference between the monotherapy or combination treatment in de novo patients.
Why studies are positive with the other antipsychotic agents but not ziprasidone may be related to the study design or just simply lack of efficacy of ziprasidone when used in combination with mood stabilizer in patients partially nonresponsive to mood stabilizer monotherapy. Of note, a previous similar study cited by the authors 7 also provided negative results. However, as the authors indicate, the absence of an active control did not provide assay sensitivity, therefore not allowing clear differentiation between a failed or negative study.
We overall praise the editor, the reviewers, the authors, and the industry sponsor for publishing a negative/failed study. As we know, wide criticism has been directed at the pharmaceutical industry for not publishing negative studies or publishing them in obscure journals. In this case, neither has occurred. We also very much welcome the publication of the companion article that attempts to explain potential pitfalls with the study design, including the possible enrollment of inappropriate subjects.
